7 results about "Hydromorphone" patented technology

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

A recombinant microbial host cell having improved in vivo conversion of reticuline and derivatives thereof (such as thebaine and / or oripavine) to relevant downstream opioids (such as neopinone, oripavine, northebaine, nororipavine or morphinone) and related compounds (such as heroin, morphine, codeine, thebaine, oripavine, oxycodone, hydrocodone, hydromorphone, oxymorphone, buprenorphine, naltrexone, naloxone or nalbuphine), wherein the microbial (such as fungal) host cell is heterologously expressing at least one functional transporter protein capable of transporting reticuline or a derivative thereof (such as thebaine and / or oripavine) and a heterologously expressed enzyme capable of acting upon reticuline or a derivative thereof. The invention also relates to uses of the microbial host cells and methods of making an opioid compound and / or opioid precursor compound and / or opioid derivative of interest.

Disclosed herein are methods that may be used for the synthesis of benzylisoquinoline alkaloids (“BIAs”) such as alkaloid morphinan. The methods disclosed can be used to produce thebaine, oripavine, codeine, morphine, oxycodone, hydrocodone, oxymorphone, hydromorphone, naltrexone, naloxone, hydroxycodeinone, neopinone, and / or buprenorphine. Compositions and organisms useful for the synthesis of BIAs, including thebaine synthesis polypeptides, purine permeases, and polynucleotides encoding the same, are provided.

1. The name of the design product: packaging box (oxycodone hydrochloride sustained-release tablets). 2. The use of the design product: packaging of pharmaceuticals. 3. The design points of the design product: in the pattern. 4. The picture or photo that best indicates the design points: front view.

This invention provides a method for preparing hydromorphone and dihydromorphine-like drugs via polyethylene glycol modification and their applications, which have the compound structure shown in general formula (I). The compounds provided by this invention reduce lipid solubility through polyethylene glycol modification, thereby slowing the rate of crossing the blood-brain barrier, slowing the release rate, prolonging the duration of action, and reducing the possibility of abuse. At high doses, they exhibit analgesic effects comparable to opioids, without producing side effects such as respiratory depression or addiction, demonstrating good safety.

The invention relates to compounds that demonstrate efficacy in blocking PACAP receptors (e.g. PAC1) and associated methods of treating neurological diseases or disorders using the disclosed compounds. The neurological diseases or disorders include, but are not limited to, stress-related diseases (e.g. chronic stress, post-traumatic stress disorder (PTSD), anxiety, or general anxiety disorder), pain-related diseases (e.g. chronic pain, primary headache disorders, or migraines), or addiction (e.g. addiction to a substance (e.g. addiction to cocaine, amphetamines, methamphetamine, methylphenidate, nicotine, alcohol, prescription medication, marijuana, tobacco, or an opioid selected from heroin, fentanyl, codeine, hydrocodone, morphine, oxycodone, hydromorphone, and methadone)).

The invention relates to a solid, analgesic dosage form for oral administration with abuse deterrent properties, said dosage form comprising: (a) one or more active ingredients having potential for abuse selected from the group consisting of Alfentanil, Benzhydrocodone, Buprenorphine, Butorphanol, Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, hydrocodone bitartrate, Hydromorphone, Levorphanol tartrate, Meperidine hydrochloride, Methadone, Morphine, Normethadone, Opium, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol, TEV-90105, ELI-202, or pharmaceutically acceptable salts and solvates thereof; (b) magnesium salt selected from the group consisting of consisting of Magnesium acetate, Magnesium benzoate, Magnesium bromate, Magnesium bromide, Magnesium carbonate, Magnesium chlorate, Magnesium chloride, Magnesium chromate, Magnesium citrate, Magnesium fluoride, Magnesium fluorosilicate, Magnesium formate, Magnesium glycinate, magnesium hydroaspartate, Magnesium hydroxide, Magnesium iodate, Magnesium iodide, Magnesium lactate, Magnesium L-threonate, Magnesium Malate, Magnesium molybdate, Magnesium nitrate, Magnesium oxalate, Magnesium oxide, Magnesium perchlorate, Magnesium phosphate, Magnesium selenite, Magnesium sulfate, Magnesium sulfate heptahydrate, Magnesium sulfite, Magnesium thiosulfate or a combination thereof, c) piperine.